BioCentury
ARTICLE | Financial News

Immune Design sets IPO range

July 14, 2014 11:28 PM UTC

Cancer immunotherapy company Immune Design Corp. (Seattle, Wash.) amended its IPO on NASDAQ and now plans to sell 4.7 million shares at $12-$14. At the $13 midpoint, the company would raise $60.5 million and be valued at $201.8 million. The company filed to raise up to $60 million in the offering last month. Jefferies; Leerink; and Wells Fargo are underwriters. ...